CytoCares Inc: Clinical Trials

4 trials sponsored by CytoCares Inc, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting. 2 Early Phase 1, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 12Recruiting 2
Phase 12Recruiting 2

Follow CytoCares Inc: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
CC312 - SLE - Systemic Lupus Erythematosus, IIM- Idiopathic Inflammatory Myopathies
Early Phase 1RecruitingCytoCares Inc62025-09-232026-04-14
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
CC312, Placebo - SLE - Systemic Lupus Erythematosus
Phase 1RecruitingCytoCares Inc322025-09-112025-09-17
Safety Study of CC312 in Autoimmune Disease Patients
CC312 - Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
Early Phase 1RecruitingCytoCares Inc182024-11-082025-09-17
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
CC312 - Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia
Phase 1RecruitingCytoCares Inc442023-08-072025-09-22

Conditions studied

Lupus Erythematosus, Systemic (3)  ·  Anemia, Hemolytic, Autoimmune (1)  ·  Arthritis, Rheumatoid (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Myositis (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Purpura, Thrombocytopenic, Idiopathic (1)  ·  Scleroderma, Systemic (1)

Countries

China (4)

Results publications

PMID 19819109, PMID 24034070, PMID 32611669